Zaaijer, H.L.

patient hbsag hepatitis level therapy hbv dna treatment baseline hepatitis b study virus hbeag-negative patients hbeag health tenofovir disoproxil fumarate hbeag-positive worker hbsag seroclearance tenofovir hepatocellular carcinoma decline health care workers hbeag-positive patients month hbeag-negative follow-up virologic response response virologic serum tdf therapy hepatitis b virus netherland seroclearance interquartile range antiretroviral therapy resistance hbsag level ef ficacy 5 years follow-up period hbeag loss immunode ficiency virus disoproxil antigen fumarate hepatology virologic breakthrough hiv /hbv patients mutation subject fi rst year department erasmus universiteit rotterdam hepatocellular follow-up evaluation carcinoma kinetic analysis liver signi period disease iatrogenic hepatitis b hbv-infected 6 years surface figure prevention person antiretroviral range committee creatinine inhibitor count infection hbv dna level baseline hbsag level ficacy